Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag? (MALS verified)
分子別名（Synonym）
LILRB2,ILT4,LIR2,MIR10,CD85d
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human LILRB2, Fc,Avitag (LI2-H82F5) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Val 461 (Accession # AAH36827.1).
Predicted N-terminus: Gln 22
蛋白結構（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 76.2 kDa. The protein migrates as 90-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
內毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
白細胞免疫球蛋白樣受體亞家族B成員2（LILRB2）也稱為CD85抗原樣家族成員D（CD85d）、免疫球蛋白類轉錄物4（ILT-4）、單核細胞/巨噬細胞免疫球蛋白狀受體10（MIR-10），它是LIR受體亞家族的B類成員。LILRB2是I類MHC抗原的受體。LILRB2識別廣泛的HLA-a、HLA-B、HLA-C和HLA-G等位基因。LILRB2與CD8A競爭結合I類MHC抗原。LILRB2/CD85d抑制FCGR1A介導的細胞蛋白磷酸化和細胞內鈣離子的動員。
關鍵字： LILRB2;LILRB2蛋白;LILRB2重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。